Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib in Recurrent or Persistent Endometrial Carcinoma
NCT00096447Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2004
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in endometrial carcinoma, sponsored by National Cancer Institute. Primary endpoints: Percentage of Patients With Progression-free Survival > 6 Months and Frequency and Severity of Adverse Events. Started Nov 2004; status: completed.
02
Drugs
lapatinib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00096447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096447.